BiotechTube
Syndya Therapeutics

Syndya Therapeutics

Basel, Switzerland· Est.
syndya-therapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Syndya Therapeutics is a private, pre-clinical stage biotech founded in 2019 and based in Schlieren, Switzerland. The company leverages a proprietary 3D combinatorial, phenotypic screening platform to discover novel drug combinations targeting complex diseases like MASH and obesity. Under the leadership of CEO Jan Lichtenberg, who has a strong background in phenotypic screening and company creation, Syndya is in stealth mode, actively seeking partners and investors to advance its pipeline. Its approach aims to tackle the multifactorial nature of metabolic diseases through innovative combination therapies.

Metabolic Dysfunction-Associated Steatohepatitis (MASH)Obesity

Technology Platform

Proprietary 3D combinatorial, phenotypic screening platform utilizing 3D cell models to discover synergistic small molecule combinations for complex diseases.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The massive and growing unmet need in MASH and obesity presents a multi-billion dollar market opportunity.
Syndya's combination therapy approach, powered by a novel 3D phenotypic screening platform, could identify differentiated treatments that address the multifactorial nature of these diseases more effectively than single-target agents.

Risk Factors

Key risks include failure to secure necessary funding, technical challenges in translating platform hits into viable drug candidates, and intense competition in the metabolic disease space from large pharma and well-funded biotechs.
The stealth mode operation also limits public validation of its progress.

Competitive Landscape

Syndya operates in the highly competitive metabolic disease arena, facing large players with approved drugs (e.g., Madrigal, Novo Nordisk, Eli Lilly) and numerous biotechs. Its differentiation lies in its combinatorial, phenotypic discovery approach, but it must demonstrate superior efficacy or novel mechanisms to secure a position.

More companies in Switzerland →